AbbVie’s Parkinson’s Disease drug meets main goal in late-stage trial

(Reuters) – AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson’s disease.

(Reporting by Sriparna Roy in Bengaluru; Editing by Anil D’Silva)